Pathophysiologic Mechanisms, Diagnosis and Management of Venous Thromboembolism

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: 28 February 2026 | Viewed by 2097

Special Issue Editor


E-Mail Website
Guest Editor
1. Department of General Surgery and Surgical Specialties, Sapienza University of Rome, 00185 Rome, Italy
2. Department of Infectious Disease, Azienda Ospedaliero-Universitaria Policlinico Umberto I, 00161 Roma, Italy
Interests: internal medicine; venous thromboembolism; cardiology; infectious disease medicine
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Venous thromboembolism (VTE)—which includes deep vein thrombosis, pulmonary embolism, and thrombosis in atypical sites (e.g., cerebral or splanchnic veins)—is associated with a relevant global burden and represents the third most common cause of death worldwide. A prompt identification of at-risk patients and an early diagnosis is of utmost importance to institute a proper therapeutic management.During the last years, several risk factors for VTE have been identified and included in specific risk assessment models for the diagnosis of VTE. Similarly, the radiological progress helped in confirming the clinical suspicion of VTE. On the therapeutic side, newer anticoagulants have been proposed with a better profile in terms of both efficacy and safety.Some grey areas, however, still remain unexplored, and a better understanding of the underlying mechanisms and risk factors for VTE development and of the diagnostic and therapeutic algorithms in specific populations is warranted. So, the aim of this Special Issue is to report recent advances in the pathophysiological mechanisms and in the diagnostic and therapeutic management of VTE.

Dr. Emanuele Valeriani
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • anticoagulants
  • deep vein thrombosis
  • diagnosis
  • pathophysiology
  • pulmonary embolism
  • venous thrombosis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 208 KB  
Article
Three Year Follow-Up of Reduced Dose of Direct Oral Anticoagulants for Extended Treatment of Venous Thromboembolism: An Ambispective Cohort Study
by Emanuele Valeriani, Arianna Pannunzio, Tommaso Brogi, Ilaria Maria Palumbo, Danilo Menichelli, Silvia Marucci, Luca Tretola, Claudio Maria Mastroianni, Daniele Pastori and Pasquale Pignatelli
Diagnostics 2025, 15(17), 2283; https://doi.org/10.3390/diagnostics15172283 - 8 Sep 2025
Viewed by 990
Abstract
Background: Few data are available on the outcomes of patients with venous thromboembolism (VTE) on long-term reduced dose of direct oral anticoagulants (DOACs). We evaluated the effectiveness and safety of reduced dose of DOACs for the extended treatment of VTE. Methods: In this [...] Read more.
Background: Few data are available on the outcomes of patients with venous thromboembolism (VTE) on long-term reduced dose of direct oral anticoagulants (DOACs). We evaluated the effectiveness and safety of reduced dose of DOACs for the extended treatment of VTE. Methods: In this monocenter, ambispective cohort study, 140 patients receiving a reduced dose of DOACs for VTE were included. The primary outcomes were recurrent VTE, major bleeding and clinically relevant non-major bleeding. The secondary outcomes were arterial events and minor bleedings. The incidence of the primary outcomes was calculated. The rate for secondary outcomes was descriptively reported. Results: The mean age of the overall cohort was 72 years. Half of the patients were female, 51.4% had a persistent risk factor, 40.0% an unprovoked VTE, and 8.6% a minor transient risk factor. Most patients had lower extremity deep vein thrombosis with or without pulmonary embolism (55.0%) and received apixaban (73.6%) or rivaroxaban (14.3%) for a mean duration of 2.7 years. Regarding the primary outcomes, there was one recurrent VTE (0.7%), four major bleedings (2.9%) and two clinically relevant non-major bleedings (1.4%). Regarding the secondary outcomes, there were four acute ischemic strokes (2.9%) and two minor bleedings (1.4%). Conclusions: Reduced dose of DOACs was associated with a low rate of recurrent VTE and an acceptably low rate of bleeding complications. The rate of arterial events during follow-up suggests the need for an assessment of cardiovascular risk factors in this study population. Full article
Back to TopTop